

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 6-K**

---

**Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934**

**April 20, 2017**

---

**Lombard Medical, Inc.  
(Exact Name of Registrant as Specified in Its Charter)**

**Commission File Number 001-36402**

---

**N/A  
(Translation of Registrant's Name into English)**

---

**Cayman Islands  
(State or Other Jurisdiction of  
Incorporation or Organization)**

**3841  
(Primary Standard Industrial  
Classification Code Number)**

**Not applicable  
(I.R.S. Employer Identification  
Number)**

**4 Trident Park  
Didcot  
Oxfordshire OX11 7HJ  
United Kingdom  
+44 20 1235 750800  
(Address, Including ZIP Code, and Telephone Number, Including Area Code, of Registrant's Principal Executive  
Offices)**

---

**Lombard Medical, Inc.  
4 Trident Park  
Didcot  
Oxfordshire OX11 7HJ  
United Kingdom  
(Name, Address of Agent for Service)**

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_

---

Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Lombard Medical, Inc. dated April 20, 2017, announcing that Kurt Lemvigh has been appointed as its new Chief Executive Officer, effective immediately.

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

### **Lombard Medical, Inc.**

Date: April 20, 2017

By: /s/ William J. Kullback  
William J. Kullback  
Chief Financial Officer

## **Lombard Medical Appoints New CEO**

OXFORDSHIRE, England--(BUSINESS WIRE)--April 20, 2017--Lombard Medical, Inc. (NASDAQ: EVAR), a developer, manufacturer and marketer of endovascular aortic aneurysm repair products, today announced that Kurt Lemvigh has been appointed as its new Chief Executive Officer, effective immediately.

Lemvigh is a veteran medical device executive with over 30 years of experience creating profitable growth. He currently resides in the U.K. and has held senior sales, marketing and operational positions at various public and private companies including Spacelabs, Cardiac Science, GE and Marquette-Hellige. In addition to Europe and the United States, Lemvigh has conducted business in numerous international markets around the world including the Middle East, Japan, China, India and Latin America.

“Lombard represents a unique opportunity given the strength of the Company’s portfolio in the over \$1.5 billion market for endovascular repair products. The key to success will be our ability to leverage the work that has been done over the years and moreover, to achieve operational excellence,” said Lemvigh. “For my part, I am committed to creating value for all of the stakeholders of Lombard.”

### **About Lombard Medical, Inc.**

Lombard Medical, Inc. based in Oxfordshire, U.K. develops, manufactures and markets an innovative range of minimally invasive abdominal aortic aneurysm endovascular repair products. The Company has global regulatory approval for Aorfix, an endovascular stent graft that has been specifically designed to treat patients with aortic neck angulation up to 90 degrees. Lombard also manufactures and markets CE-marked Altura, an ultra-low profile endovascular stent graft that offers a simple and predictable solution for the treatment of standard AAA anatomies. The Altura endograft system is sold in select European markets. For more information, please visit [www.lombardmedical.com](http://www.lombardmedical.com).

### **CONTACT:**

#### **Lombard Medical, Inc.**

William J. Kullback, +1-858-750-5245

Chief Financial Officer

[bill.kullback@lombardmedical.com](mailto:bill.kullback@lombardmedical.com)